BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Notas G, Kolios G, Mastrodimou N, Kampa M, Vasilaki A, Xidakis C, Castanas E, Thermos K, Kouroumalis E. Cortistatin production by HepG2 human hepatocellular carcinoma cell line and distribution of somatostatin receptors. J Hepatol. 2004;40:792-798. [PMID: 15094227 DOI: 10.1016/j.jhep.2004.01.016] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, Zisimopoulos A, Andriotis E, Panagiotakos D, Fotopoulou A, Chrysohoou C, Bazinis A, Daskalopoulou D, Paraskevas E. Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: Randomized placebo-controlled trial. World J Gastroenterol 2007; 13(23): 3164-3170 [PMID: 17589893 DOI: 10.3748/wjg.v13.i23.3164] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 39] [Article Influence: 2.5] [Reference Citation Analysis]
2 Ayiomamitis GD, Notas G, Zaravinos A, Drygiannakis I, Georgiadou M, Sfakianaki O, Mastrodimou N, Thermos K, Kouroumalis E. Effects of octreotide and insulin on colon cancer cellular proliferation and correlation with hTERT activity. Oncoscience 2014;1:457-67. [PMID: 25594044 DOI: 10.18632/oncoscience.58] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
3 Notas G, Kampa M, Nifli AP, Xidakis K, Papasava D, Thermos K, Kouroumalis E, Castanas E. The inhibitory effect of opioids on HepG2 cells is mediated via interaction with somatostatin receptors. Eur J Pharmacol 2007;555:1-7. [PMID: 17113072 DOI: 10.1016/j.ejphar.2006.10.018] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
4 Samonakis DN, Christodoulakis N, Kouroumalis EA. Octreotide for unresectable hepatocellular carcinoma: beyond the first sight. J Clin Gastroenterol 2006;40:86-7. [PMID: 16340641 DOI: 10.1097/01.mcg.0000190778.50279.26] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
5 Hasskarl J, Kaufmann M, Schmid HA. Somatostatin receptors in non-neuroendocrine malignancies: the potential role of somatostatin analogs in solid tumors. Future Oncology 2011;7:895-913. [DOI: 10.2217/fon.11.66] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
6 Allia E, Tarabra E, Volante M, Cerrato M, Ghigo E, Muccioli G, Papotti M. Expression of cortistatin and MrgX2, a specific cortistatin receptor, in human neuroendocrine tissues and related tumours. J Pathol 2005;207:336-45. [DOI: 10.1002/path.1839] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 1.8] [Reference Citation Analysis]
7 Tsagarakis NJ, Drygiannakis I, Batistakis AG, Kolios G, Kouroumalis EA. Octreotide induces caspase activation and apoptosis in human hepatoma HepG2 cells. World J Gastroenterol 2011; 17(3): 313-321 [PMID: 21253389 DOI: 10.3748/wjg.v17.i3.313] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
8 Zhang HY, Xu WQ, Zheng YY, Omari-Siaw E, Zhu Y, Cao X, Tong SS, Yu JN, Xu XM. Octreotide-periplocymarin conjugate prodrug for improving targetability and anti-tumor efficiency: synthesis, in vitro and in vivo evaluation. Oncotarget 2016;7:86326-38. [PMID: 27861145 DOI: 10.18632/oncotarget.13389] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
9 de Lecea L. Cortistatin--functions in the central nervous system. Mol Cell Endocrinol 2008;286:88-95. [PMID: 18374474 DOI: 10.1016/j.mce.2007.12.014] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 3.6] [Reference Citation Analysis]
10 Somvanshi RK, Kumar U. δ-opioid receptor and somatostatin receptor-4 heterodimerization: possible implications in modulation of pain associated signaling. PLoS One 2014;9:e85193. [PMID: 24416361 DOI: 10.1371/journal.pone.0085193] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
11 Tsagarakis NJ, Drygiannakis I, Batistakis AG, Kolios G, Kouroumalis EA. A concentration-dependent effect of ursodeoxycholate on apoptosis and caspases activities of HepG2 hepatocellular carcinoma cells. European Journal of Pharmacology 2010;640:1-7. [DOI: 10.1016/j.ejphar.2010.04.023] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
12 Wan Z, Wang X. Role of SLC39A6 in the development and progression of liver cancer. Oncol Lett 2022;23:77. [PMID: 35111246 DOI: 10.3892/ol.2022.13197] [Reference Citation Analysis]
13 Scheele JS, Harder J, Stankovic Z, Räpple D, Dorn A, Spangenberg HC, Blum HE. Clinical response to Auron Misheil Therapy in a man with advanced multifocal hepatocellular carcinoma: A case report. J Med Case Rep 2011;5:478. [PMID: 21943068 DOI: 10.1186/1752-1947-5-478] [Reference Citation Analysis]
14 Kaemmerer D, Schindler R, Mußbach F, Dahmen U, Altendorf-Hofmann A, Dirsch O, Sänger J, Schulz S, Lupp A. Somatostatin and CXCR4 chemokine receptor expression in hepatocellular and cholangiocellular carcinomas: tumor capillaries as promising targets. BMC Cancer 2017;17:896. [PMID: 29282035 DOI: 10.1186/s12885-017-3911-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
15 Broglio F, Papotti M, Muccioli G, Ghigo E. Brain–gut communication: cortistatin, somatostatin and ghrelin. Trends in Endocrinology & Metabolism 2007;18:246-51. [DOI: 10.1016/j.tem.2007.06.004] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 2.3] [Reference Citation Analysis]
16 Gaviglio L, Gross A, Metzler-Nolte N, Ravera M. Synthesis and in vitro cytotoxicity of cis,cis,trans-diamminedichloridodisuccinatoplatinum(IV)-peptide bioconjugates. Metallomics 2012;4:260-6. [PMID: 22310724 DOI: 10.1039/c2mt00171c] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 5.2] [Reference Citation Analysis]
17 Borbath I, Leclercq IA, Abarca-Quinones J, Desaeger C, Lebrun V, Moulin P, Sempoux C, Horsmans Y. Inhibition of early preneoplastic events in the rat liver by the somatostatin analog lanreotide. Cancer Sci 2007;98:1831-9. [PMID: 17900309 DOI: 10.1111/j.1349-7006.2007.00626.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
18 Lasfer M, Vadrot N, Schally AV, Nagy A, Halmos G, Pessayre D, Feldmann G, Reyl-Desmars FJ. Potent induction of apoptosis in human hepatoma cell lines by targeted cytotoxic somatostatin analogue AN-238. J Hepatol 2005;42:230-7. [PMID: 15664249 DOI: 10.1016/j.jhep.2004.10.014] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
19 Zhang X, Ng HLH, Lu A, Lin C, Zhou L, Lin G, Zhang Y, Yang Z, Zhang H. Drug delivery system targeting advanced hepatocellular carcinoma: Current and future. Nanomedicine. 2016;12:853-869. [PMID: 26772424 DOI: 10.1016/j.nano.2015.12.381] [Cited by in Crossref: 66] [Cited by in F6Publishing: 61] [Article Influence: 11.0] [Reference Citation Analysis]
20 Bhandari S, Watson N, Long E, Sharpe S, Zhong W, Xu SZ, Atkin SL. Expression of somatostatin and somatostatin receptor subtypes 1-5 in human normal and diseased kidney. J Histochem Cytochem 2008;56:733-43. [PMID: 18443363 DOI: 10.1369/jhc.2008.950998] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
21 Szepeshazi K, Schally AV, Treszl A, Seitz S, Halmos G. Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin. Anti-Cancer Drugs 2008;19:349-58. [DOI: 10.1097/cad.0b013e3282f9adce] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
22 Xidakis C, Mastrodimou N, Notas G, Renieri E, Kolios G, Kouroumalis E, Thermos K. RT-PCR and immunocytochemistry studies support the presence of somatostatin, cortistatin and somatostatin receptor subtypes in rat Kupffer cells. Regul Pept. 2007;143:76-82. [PMID: 17481746 DOI: 10.1016/j.regpep.2007.03.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
23 Zou YX, Shen WZ, Liao ST, Liu F, Zheng SQ, Blumberg JB, Chen CY. Mulberry leaf phenolics ameliorate hyperglycemia-induced oxidative stress and stabilize mitochondrial membrane potential in HepG2 cells. Int J Food Sci Nutr 2014;65:960-6. [PMID: 25026091 DOI: 10.3109/09637486.2014.940285] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
24 Durán-Prado M, Gahete MD, Martínez-Fuentes AJ, Luque RM, Quintero A, Webb SM, Benito-López P, Leal A, Schulz S, Gracia-Navarro F, Malagón MM, Castaño JP. Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors. J Clin Endocrinol Metab 2009;94:2634-43. [PMID: 19401364 DOI: 10.1210/jc.2008-2564] [Cited by in Crossref: 106] [Cited by in F6Publishing: 107] [Article Influence: 8.2] [Reference Citation Analysis]
25 Zhang HY, Xu WQ, Wang YW, Omari-Siaw E, Wang Y, Zheng YY, Cao X, Tong SS, Yu JN, Xu XM. Tumor targeted delivery of octreotide-periplogenin conjugate: Synthesis, in vitro and in vivo evaluation. Int J Pharm 2016;502:98-106. [PMID: 26899980 DOI: 10.1016/j.ijpharm.2016.02.024] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
26 Borbath I, Leclercq IA, Sempoux C, Abarca-quinones J, Desaeger C, Horsmans Y. Efficacy of lanreotide in preventing the occurrence of chemically induced hepatocellular carcinoma in rats. Chemico-Biological Interactions 2010;183:238-48. [DOI: 10.1016/j.cbi.2009.10.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
27 Samonakis DN, Notas G, Christodoulakis N, Kouroumalis EA. Mechanisms of action and resistance of somatostatin analogues for the treatment of hepatocellular carcinoma: a message not well taken. Dig Dis Sci. 2008;53:2359-2365. [PMID: 18273705 DOI: 10.1007/s10620-007-0175-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
28 Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, Zisimopoulos A, Andriotis E, Panagiotakos D, Fotopoulou A, Chrysohoou C, Bazinis A, Daskalopoulou D. Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: randomized placebo-controlled trial. World J Gastroenterol. 2007;13:3164-3170. [PMID: 17589893 DOI: 10.3748/wjg.v13.i13.3164] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Notas G, Nifli AP, Kampa M, Pelekanou V, Alexaki VI, Theodoropoulos P, Vercauteren J, Castanas E. Quercetin accumulates in nuclear structures and triggers specific gene expression in epithelial cells. J Nutr Biochem 2012;23:656-66. [PMID: 21782406 DOI: 10.1016/j.jnutbio.2011.03.010] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 3.1] [Reference Citation Analysis]
30 Pivonello C, De Martino MC, Negri M, Cuomo G, Cariati F, Izzo F, Colao A, Pivonello R. The GH-IGF-SST system in hepatocellular carcinoma: biological and molecular pathogenetic mechanisms and therapeutic targets. Infect Agent Cancer 2014;9:27. [PMID: 25225571 DOI: 10.1186/1750-9378-9-27] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
31 Volante M, Rosas R, Allìa E, Granata R, Baragli A, Muccioli G, Papotti M. Somatostatin, cortistatin and their receptors in tumours. Mol Cell Endocrinol. 2008;286:219-229. [PMID: 18248880 DOI: 10.1016/j.mce.2007.12.002] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 2.7] [Reference Citation Analysis]